Study Comparing Emergency Contraception Effectiveness in Women Who Weight ≥ 80 kg



Status:Recruiting
Conditions:Contraception, Contraception, Hospital
Therapuetic Areas:Other, Reproductive
Healthy:No
Age Range:18 - 40
Updated:8/3/2018
Start Date:July 12, 2018
End Date:August 1, 2019
Contact:Amber Blackmon
Email:sblackmon@healthdec.com
Phone:919-967-1111

Use our guide to learn which trials are right for you!

A Multi-center, Randomized Study of the Efficacy of Ulipristal Acetate (UPA) 30 mg, Levonorgestrel (LNG) 1.5 mg, and LNG 3.0 mg for Emergency Contraception (EC) in Women With Weight ≥ 80 kg

The proposed research study is a Phase IIb, multi-center, single-blind, randomized study of
UPA 30 mg, LNG 1.5 mg and LNG 3.0 mg to evaluate EC effectiveness in women with weight ≥ 80
kg who present within 72 hours of unprotected intercourse.

Orally-dosed emergency contraception (EC) is highly effective when used properly. EC is up to
90% effective at preventing pregnancy following unprotected intercourse. Both ulipristal
acetate (UPA) and levonorgestrel (LNG) delay or inhibit ovulation when used for EC. For
individual women, use of EC provides a critical backup to prevent unintended pregnancy.

However, obesity may severely impair EC effectiveness. Data from two large randomized control
trials to identify risk factors for EC failure. A woman of obese body mass index (BMI)
(≥30mg/kg2) using LNG-based EC had more than a 4 times greater risk of pregnancy compared to
her normal BMI counterpart and a woman of overweight BMI (25-29.9) was at twice the risk of
pregnancy. Failure was also associated with a high body weight. LNG-based EC appears to have
a ceiling of efficacy at 70 kg and no efficacy for women 80 kg and above. It is believed that
by doubling the dose to LNG 3.0 mg, serum levels of LNG are corrected to a therapeutic range.

Inclusion Criteria:

1. Be in good general overall health with no chronic medical conditions that result in
periodic exacerbations that require significant medical care.

2. Between 18 and 40 years inclusive at the enrollment visit.

3. Weight ≥ 80 kg.

4. Have regular menstrual cycles that typically occur every 21-35 days when not using
hormonal contraception.

5. If subject is postpartum or post-abortal, she must have experienced a menstrual bleed
since the pregnancy ended

6. If a subject recently used non-injectable hormonal contraception, one bleeding episode
consistent with menses must have occurred since last use;

7. Willing to avoid use of any hormonal or intrauterine contraception until the end of
the study;

8. For women with a recent history of Depo Provera use, the most recent injection must
have been at least 6 months before study entry, and the subject must have had at least
one normal menstrual cycle (2 consecutive menses);

9. Request emergency contraception within 72 hours (3 days) after unprotected coitus, as
defined by lack of contraceptive use, condom breakage (including condoms lubricated
with spermicide), or other barrier contraceptive method failure;

10. Have a negative urine pregnancy test at time of screening

11. Reports all acts of unprotected coitus since her prior menses are within 72 hours
prior to enrollment;

12. Willing to abstain from further acts of unprotected intercourse until the end of the
study;

13. Give voluntary, written informed consent, and agree to observe all study requirements
including being available for follow up for at least the next 4 weeks;

14. Accepts that the risk of pregnancy with oral EC is greater than that following
placement of a copper IUD for EC.

Exclusion Criteria:

1. Be currently pregnant (positive high-sensitivity urine pregnancy test);

2. Be currently breastfeeding or within 30 days of discontinuing breastfeeding, unless
the subject has already had a menses following discontinuation of breastfeeding;

3. Desire to use hormonal systemic contraception within 5 days of study drug use

4. Have had a female sterilization procedure;

5. Have a partner with a history of vasectomy;

6. Current inability to tolerate oral medication;

7. Have impaired hypothalamic-pituitary-adrenal reserve or oral glucocorticoid
replacement therapy in the last year.

8. Have known liver disease;

9. Have known liver abnormalities with elevated enzymes at least twice the upper limit of
normal requiring use of liver enzyme inducers.

10. Have known hypersensitivity to the active substance UPA or LNG, or any of the
excipients of the study treatment.

11. Have a current need for exogenous hormones.

12. Have concomitant use of strong CYP3A4 inhibitors (as identified by the FDA) or
inducers at the time of or planned use within 3 days of dosing;

13. Use any medications that can interfere with the metabolism of hormonal contraceptives;
take antibiotics that can interfere with metabolism of hormonal contraceptives at the
time of or planned use within 3 days of dosing of the study drug; or use any drugs
designated by the FDA as falling in the Pregnancy and Lactation narrative subsections
(formerly Category D or X medications).

14. Current or recent (within one month) participation in any other trial of an
investigational medicine or device or planning to participate in another clinical
trial during this study.

15. Have a history of a bariatric surgery procedure associated with malabsorption.

16. Live outside of the catchment area of the study site.

17. Have used UPA or LNG EC within 30 days prior to enrollment and not had a menses since
using the drug.

18. Be a site staff member with delegated study responsibilities or a family member of a
site staff member with delegated study responsibilities. -
We found this trial at
18
sites
101 Dudley St
Providence, Rhode Island 02905
(401) 274-1100
Women and Infants Hospital of Rhode Island Women & Infants Hospital of Rhode Island, a...
?
mi
from
Providence, RI
Click here to add this to my saved trials
5801 South Ellis Avenue
Chicago, Illinois 60637
 773.702.1234
University of Chicago One of the world's premier academic and research institutions, the University of...
?
mi
from
Chicago, IL
Click here to add this to my saved trials
2500 Campus Rd
Honolulu, Hawaii 96822
(808) 956-8111
Principal Investigator: Bliss Kaneshiro, MD
Phone: 808-203-6594
Univ of Hawaii Honolulu Community College is an integral part of the University of Hawai?i,...
?
mi
from
Honolulu, HI
Click here to add this to my saved trials
116th St and Broadway
New York, New York 10027
(212) 854-1754
Principal Investigator: Carolyn Westhoff
Phone: 212-305-8031
Columbia University In 1897, the university moved from Forty-ninth Street and Madison Avenue, where it...
?
mi
from
New York, NY
Click here to add this to my saved trials
Norfolk, Virginia 23507
Principal Investigator: David Archer
Phone: 757-446-7161
?
mi
from
Norfolk, VA
Click here to add this to my saved trials
3181 Southwest Sam Jackson Park Road
Portland, Oregon 97239
503 494-8311
Principal Investigator: Alison Edelman
Phone: 503-494-3173
Oregon Health and Science University In 1887, the inaugural class of the University of Oregon...
?
mi
from
Portland, OR
Click here to add this to my saved trials
201 Presidents Circle
Salt Lake City, Utah 84108
801) 581-7200
Principal Investigator: David Turok, MD
Phone: 801-213-2774
University of Utah Research is a major component in the life of the U benefiting...
?
mi
from
Salt Lake City, UT
Click here to add this to my saved trials
4940 Eastern Ave
Baltimore, Maryland 21224
(410) 550-0100
Principal Investigator: Anne Burke
Phone: 410-550-8506
Johns Hopkins Bayview Medical Center There is no better story in American medicine in the...
?
mi
from
Baltimore, MD
Click here to add this to my saved trials
Boston, Massachusetts 02215
Principal Investigator: Alisa Goldberg, MD
?
mi
from
Boston, MA
Click here to add this to my saved trials
Cincinnati, Ohio 45267
Principal Investigator: Michael Thomas, MD
Phone: 513-584-4130
?
mi
from
Cincinnati, OH
Click here to add this to my saved trials
Cleveland, Ohio 44106
Principal Investigator: James H. Liu, MD
Phone: 440-720-3250
?
mi
from
Cleveland, OH
Click here to add this to my saved trials
Denver, Colorado 80210
Principal Investigator: Stephanie Teal, MD
?
mi
from
Denver, CO
Click here to add this to my saved trials
3600 Wilshire Boulevard
Los Angeles, California 90010
Principal Investigator: Anita Nelson
Phone: 213-386-5614
?
mi
from
Los Angeles, CA
Click here to add this to my saved trials
New York, New York 10016
Principal Investigator: Treasure Walker
Phone: 212-263-6253
?
mi
from
New York, NY
Click here to add this to my saved trials
3451 Walnut St
Philadelphia, Pennsylvania 19104
1 (215) 898-5000
Principal Investigator: Courtney Schreiber, MD
Univ of Pennsylvania Penn has a long and proud tradition of intellectual rigor and pursuit...
?
mi
from
Philadelphia, PA
Click here to add this to my saved trials
Pittsburgh, Pennsylvania 15213
Principal Investigator: Beatrice Chen, MD
?
mi
from
Pittsburgh, PA
Click here to add this to my saved trials
1 Shields Ave
Sacramento, California 95616
(530) 752-1011
Principal Investigator: Mitchell Creinin
Phone: 916-734-6846
University of California-Davis As we begin our second century, UC Davis is poised to become...
?
mi
from
Sacramento, CA
Click here to add this to my saved trials
San Francisco, California 94143
Principal Investigator: Philip Darney, MD
?
mi
from
San Francisco, CA
Click here to add this to my saved trials